Alan Meds vs Aquivia Health
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alan Meds
Best for budget-conscious shoppersStarting at $99/mo
Aquivia Health
Best for Self-pay patients who want a clinician-reviewed (not algorithmic) compounded-GLP-1 pathway at the low end of the WLR compounded cluster ($149/mo semaglutide, $179/mo tirzepatide) AND want the option to upgrade to branded Ozempic/Zepbound at the same operator. Buyers who value a named clinical MSO partner (Open Loop Healthcare Partners, PC) and a co-founder team that publicly discloses credentials (MD + PharmD + operations executive). NOT ideal for buyers who require an upfront state-availability disclosure (Aquivia does not publish a state allowlist), buyers who require LegitScript/PCAB/BBB badges in the footer as a precondition (none visible in this verification pass), or buyers in coming-soon program categories (Performance Longevity, Dysautonomia/POTS are waitlist-only).Starting at $149/mo
Side-by-Side Comparison
| Feature | Alan Meds | Aquivia Health |
|---|---|---|
| Overall Score | ✓7.7/10 | 6.9/10 |
| Starting Price | ✓$99/mo | $149/mo |
| Editorial Rating | ✓3.9 ★ /5 | 3.5 ★ /5 |
| Features | 5 features | ✓10 features |
| States Available | ✓46 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | ✓None | 4 warnings |
Pros & Cons
Alan Meds
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Cons
- ✗Limited public information on program details
Aquivia Health
Pros
- ✓Named clinical partner disclosed verbatim in site footer: 'Clinical care services provided by our partner clinicians at Open Loop Healthcare Partners, PC: openloophealth.com' — same MSO network used by several other DTC GLP-1 brands, which is a reused-and-verified trust signal
- ✓Named leadership team with credentials disclosed: Steven Bishop MD (CMO, Internal Medicine), Phillip Gray PharmD (Chief Pharmacist, 503A/USP background), Tom Foster (President)
- ✓Itemized pricing displayed publicly on /pricing and /programs/glp-1-weight-loss — Compounded Semaglutide $149/mo, Compounded Tirzepatide $179/mo, Ozempic $1,299/shipment, Zepbound $1,399/shipment
- ✓Both compounded AND branded GLP-1 options offered side-by-side, which is unusual — most DTC compounded providers do not also carry branded Ozempic/Zepbound
- ✓Self-pay model with no insurance required and no separate consultation fee (consult bundled into the monthly product price)
- ✓Multi-month prepay discounts disclosed publicly ('save $910 vs billed every 4 weeks' on 52-week semaglutide and tirzepatide tiers)
- ✓Explicit no-guarantee disclaimer ('Completing the check does not guarantee a prescription') is a positive clinical-safety signal vs platforms that imply guaranteed prescriptions
- ✓Multi-program platform with metabolic, longevity, and dysautonomia pathways (latter two waitlist-only) suggests a broader clinical scope than single-vertical compounded shops
Cons
- ✗No public state-availability allowlist — marketing copy says 'Nationwide distribution *where allowed by state law' but the FAQ acknowledges 'Not all therapies are available in every state' without disclosing which states are excluded; buyer must complete the eligibility intake to learn whether their state qualifies
- ✗No named 503A compounding pharmacy partner disclosed publicly — the homepage and pricing page reference '503A Pharmacy Standard' and 'licensed 503A compounding pharmacies' but do not name a specific pharmacy operator, limiting independent licensure verification
- ✗No LegitScript, PCAB, or BBB trust-signal badges visible on the homepage footer in this verification pass — a meaningful omission for a DTC compounded-GLP-1 platform launched 2026-Q1 (site Schema.org datePublished 2026-04-21)
- ✗Brand confusion risk: schema.org Organization name on the homepage is 'CatalystMD' (with a CatalystMD logo file referenced) while the customer-facing brand is 'Aquivia Health' — the parent/operating-entity relationship is not disclosed in the public footer or About page in this verification pass
- ✗Compounded semaglutide and tirzepatide are not FDA-approved and have not undergone FDA premarket review for safety, efficacy, or manufacturing quality
- ✗Site is recently launched (Schema.org datePublished 2026-04-21, dateModified 2026-05-24) with no Trustpilot, BBB, or third-party-reviews profile yet that could be independently verified
- ✗Two of the three advertised programs (Performance Longevity, Dysautonomia/POTS) are waitlist-only — only the GLP-1 Weight Loss / Metabolic Health pathway is currently 'Available Now'
Our Verdict
Alan Meds edges out Aquivia Health with a higher overall score of 7.7/10 and is particularly strong for budget-conscious shoppers. Aquivia Health remains a solid alternative, especially if you're looking for Self-pay patients who want a clinician-reviewed (not algorithmic) compounded-GLP-1 pathway at the low end of the WLR compounded cluster ($149/mo semaglutide, $179/mo tirzepatide) AND want the option to upgrade to branded Ozempic/Zepbound at the same operator. Buyers who value a named clinical MSO partner (Open Loop Healthcare Partners, PC) and a co-founder team that publicly discloses credentials (MD + PharmD + operations executive). NOT ideal for buyers who require an upfront state-availability disclosure (Aquivia does not publish a state allowlist), buyers who require LegitScript/PCAB/BBB badges in the footer as a precondition (none visible in this verification pass), or buyers in coming-soon program categories (Performance Longevity, Dysautonomia/POTS are waitlist-only)..
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring Alan Meds and Aquivia Health head-to-heads in the same category.
- Alan Meds vs CoreAge Rx
- Alan Meds vs TrimRx
- Alan Meds vs Amazon One Medical
- Aquivia Health vs NovoCare Pharmacy
- Aquivia Health vs Vytora Health
- Aquivia Health vs Enhance MD
Or see the full category ranking.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.